TABLE 1.

Plasma creatinine and AMB concentrations after administration of a single i.v. dose of DOC-AMB and a single administration by oral gavage of DOC-AMB and various AMB lipid formulations to male Sprague-Dawley rats

Treatment group and/or route of administration	Dose (mg/kg)	Plasma creatinine levela			Tmax (h)	Cmax (μg/ml)	AUC0-24 (μg · h/ml)
		Concn prior to dose (mg/dl)	Concn 24 h after dose (mg/dl)	% Change from baseline
DOC-AMB
i.v.	1	0.38 ± 0.13	0.71 ± 0.10b	+87			4.3 ± 1.1
Oral	5	0.34 ± 0.07	0.29 ± 0.05	−15	NDc	ND	ND
Oral	50	0.29 ± 0.07	0.42 ± 0.02b	+45	8	39.8 ± 22	519 ± 209d
AMB-lipid formulations
ABLC	50	0.45 ± 0.01	0.24 ± 0.07b	−47	10	48.5 ± 26	542 ± 271
Intralipid-AMB	50	0.27 ± 0.02	0.38 ± 0.02b	+33	2	769 ± 213e	5,984 ± 3,461e
Peceol AMB	50	0.48 ± 0.10	0.65 ± 0.07	+35	4	1,469 ± 891e	11,407 ± 4,971e
	5	0.44 ± 0.06	0.39 ± 0.06	−11	2	1,187 ± 409e	4,415 ± 2,411e

^aData presented as means ± standard deviations (n = 6).

^bSignificantly difference from values prior to dose (P < 0.05).

^cND, not determinable.

^dSignificantly difference from DOC-AMB i.v. value (P < 0.05).

^eSignificantly different from AUC_0-24 value for ABLC (P < 0.05).